The involvement of major pharmaceutical and biotechnology companies in the Wilson's Disease (WD) space has dramatically accelerated the pace of innovation and fundamentally altered market dynamics. Historically, the market was characterized by a few legacy drugs and a limited number of dedicated players, reflective of its rare disease status. Today, driven by the lure of Orphan Drug Designation...